Eledon Pharmaceuticals (ELDN) Liabilities and Shareholders Equity (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $146.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.08% year-over-year to $146.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $590.4 million (up 2.91% YoY) and the FY2025 annual result came in at $169.0 million, down 4.73% from the prior year.
• Liabilities and Shareholders Equity retreated to $146.7 million in Q1 2026, from $169.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $177.4 million in Q4 2024 to a low of $80.8 million in Q1 2024.
• A 5-year average of $128.1 million and a median of $129.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 49.0% — and 2025, when it soared 99.59%.
• Tracing ELDN's Liabilities and Shareholders Equity over 5 years: stood at $92.8 million in 2022, then declined by 4.02% to $89.1 million in 2023, then surged by 99.18% to $177.4 million in 2024, then dropped by 4.73% to $169.0 million in 2025, then declined by 13.22% to $146.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $146.7 million (Q1 2026), $169.0 million (Q4 2025), and $129.9 million (Q3 2025), per Business Quant data.